TOL 101

Drug Profile

TOL 101

Alternative Names: TOL-101

Latest Information Update: 23 Sep 2015

Price : $50

At a glance

  • Originator The Cleveland Clinic Foundation
  • Developer Tolera Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection; Type 1 diabetes mellitus
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 23 Sep 2015 No recent reports on development identified - Preclinical for Type-1 diabetes mellitus in USA (unspecified route)
  • 23 Sep 2015 No recent reports on development identified - Phase-I/II for Transplant rejection (Prevention) in USA (IV)
  • 16 Oct 2012 Tolera Therapeutics plans a phase III trial for Transplant rejection (prevention) in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top